Technical Analysis for SLS - SELLAS Life Sciences Group, Inc.

Grade Last Price % Change Price Change
grade C 3.58 0.28% 0.01
SLS closed up 0.28 percent on Wednesday, August 5, 2020, on 47 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical SLS trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.28%
Calm After Storm Range Contraction 0.28%
New Uptrend Bullish 2.58%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.58%
Calm After Storm Range Contraction 2.58%
Upper Bollinger Band Walk Strength 2.58%
Inside Day Range Contraction 2.58%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Biopharmaceutical Cancer Clinical Medicine Oncology Solid Tumors Cancer Treatments GPS Acute Myeloid Leukemia Breast Cancer Ovarian Cancer Antineoplastic Drugs Immunotherapies Hematologic Malignancies Oncolytics Biotech Treatment Of Acute Myeloid Leukemia Gynaecology Treatment Of Breast Cancer Novel Cancer Gynaecological Cancer National Park Service Ovarian And Endometrial Cancers Pembrolizumab

Is SLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.86
52 Week Low 1.455
Average Volume 214,237
200-Day Moving Average 3.33
50-Day Moving Average 3.23
20-Day Moving Average 3.20
10-Day Moving Average 3.38
Average True Range 0.28
ADX 31.81
+DI 35.62
-DI 7.47
Chandelier Exit (Long, 3 ATRs ) 3.60
Chandelier Exit (Short, 3 ATRs ) 3.57
Upper Bollinger Band 3.66
Lower Bollinger Band 2.73
Percent B (%b) 0.91
BandWidth 29.04
MACD Line 0.12
MACD Signal Line 0.07
MACD Histogram 0.0485
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.79
Resistance 3 (R3) 3.80 3.73 3.76
Resistance 2 (R2) 3.73 3.68 3.73 3.74
Resistance 1 (R1) 3.66 3.65 3.63 3.65 3.73
Pivot Point 3.59 3.59 3.58 3.59 3.59
Support 1 (S1) 3.52 3.54 3.49 3.51 3.43
Support 2 (S2) 3.45 3.51 3.45 3.42
Support 3 (S3) 3.38 3.45 3.41
Support 4 (S4) 3.37